广誉远经典名方产品龟龄集 广誉远中医药文化产业园 在广誉远的博物馆里，讲解员指着升炼核心产品龟龄集的椭圆形炼丹炉说："最早时候我们用这个银炉 升炼，后来改良了，但核心原理未变。"正是这种对古法炮制的坚持让"中华老字号"广誉远品牌驰名海 内外中药界。 ◎记者 陈芳 一家近500年历史的中华老字号企业，是如何历经时代更迭后依然闪闪发光？近日，上海证券报记者走 进广誉远工厂，探寻其穿越时间长河的密码。在广誉远董事长李晓军看来，面对行业竞争加剧和科技浪 潮推陈出新、不断迭代，广誉远只有"跑"起来，不断地自我革命，自我完善，才能实现突破，跻身行业 第一梯队。 尊古不囿古，为守护药效 在全透明的玻璃厂房内，数以百计的大醋缸依次整齐排开，大醋缸表面盖有玻璃板，旁边有卡片记录着 晾晒时间和批次。经过这样长达三年的日晒夜露，二十公斤陈醋才能浓缩成一公斤的醋膏。 醋膏仅仅是炮制鹿茸的一味辅料，还需将醋膏加入鹿茸中土埋，经过独特的多种炮制后研成细末。系列 的繁琐工艺耗时漫长，广誉远却坚守了传统炮制的古法。 在广誉远生产工艺里，古法炮制随处可见。比如水飞法制作朱砂、土炒白术以及地黄九蒸九晒等。长期 以来，广誉远总结出了炒、蒸、煮、熏 ...

广誉远（600771.SH）12月9日在投资者互动平台表示，您好，感谢您的关注。公司产品龟龄集（30 粒）的官方指导零售价为598元/盒，公司并未对其进行调整。线上店铺销售价格受平台活动政策、满减 优惠及新人福利等多项因素影响，价格在合理区间内波动属正常情况。 每经AI快讯，有投资者在投资者互动平台提问：请问龟龄集（30粒）官方市场指导零售价是多少一 盒？微店广誉远大健康商城销售价为528元/盒，请问最近销售价是否提价了？ （记者 曾健辉） ...

证券日报网讯12月9日，广誉远（600771）在互动平台回答投资者提问时表示，目前，公司管理团队稳 定，各项工作均有序推进，不存在应披未披事项。 ...

（记者 曾健辉） 每经AI快讯，有投资者在投资者互动平台提问：根据中药材天地网发布的公司公开招标采购的大宗药 材统计，今年采购药材量达到47万余千克，是2024年采购量的3.6倍，是因为公司核心药品产量增加还 是代工大健康品增加？ 广誉远（600771.SH）12月9日在投资者互动平台表示，您好，感谢您的关注。公司采购各种药材均是 生产自有产品，采购量是综合考虑生产供应、价格行情、需求响应和战略考量等因素实施的。 ...

新三板公司元和药业12月2日公告，公司董事关平先生于2025年12月1日因意外不幸去世。 中国药店视频截图 公开资料显示，关平是中国医药行业的资深职业经理人，曾获得过全国十佳职业经理人，十佳医药精英等奖项，是不少职业经理人眼中的老师、兄长，更 有不少人尊称他为"关爷"。 他先后在西安杨森、丽珠集团、惠氏制药、石药集团、东盛科技等药企工作过。 据智通财经报道，在国内医药市场的草莽年代，关平曾操盘钙尔奇、白加黑等亿级单品，被业内冠以"OTC（非处方药）王子"之名。"关爷这个称呼和资 历、年龄、讲规矩，做人做事儿、体面相关，也带着自我和洒脱的意味。"一位关平的业内好友在悼念他的视频中这样说道。 关平曾自述，"1983年从西安理工大学毕业后，我留校当老师。当时，下海潮渐起，经历了一番思想斗争，1988年我辞掉"铁饭碗"，加入西安杨森，成为 这家合资药企的第二名本土医药代表。" 他职业生涯的一大转折则发生在1997年加入惠氏－白宫公司做大区市场总监。外籍总经理P.K打动关平的一句话是"进入我们公司，你就站在了潮流的最前 头。"当时，该公司主打产品钙尔奇D退出公费药目录名单，因而从院内转向OTC零售市场。而后者还是一片药 ...

证券代码：600771 证券简称：广誉远 编号：临 2025-020 广誉远中药股份有限公司 本次控股股东与实际控制人之间产权层级减少系山西省人民政府将山西省国有 资本运营有限公司（以下简称"山西国资运营公司"）持有的神农科技集团有 限公司（以下简称"神农科技集团"）74.15%股权划转至山西省人民政府国有 资产监督管理委员会（以下简称"山西省国资委"）直接持有。 本次控股股东与实际控制人之间产权层级减少不会导致公司直接控股股东及实 际控制人发生变化。公司直接控股股东仍为神农科技集团，实际控制人仍为山 西省国资委。 本次控股股东与实际控制人之间产权层级减少不涉及要约收购。 本次划转前，公司的股权控制关系如下图所示： 关于控股股东与实际控制人之间产权层级减少的提示性 公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： 一、本次控股股东与实际控制人之间产权层级减少的基本情况 近日，广誉远中药股份有限公司（以下简称"公司"）收到控股股东神农科技集团 转来的《山西省人民政府国有资产监督管理委员会关于将山西省国有 ...

Personnel Changes - Yunnan Baiyao announced the election of Zhang Wenxue as chairman and Dong Ming as vice chairman during the first meeting of the 11th board of directors on November 10, 2025 [2] - China National Pharmaceutical Group (Sinopharm) reported the resignation of Zhao Bingxiang from multiple positions, including non-executive director and chairman, with Jin Bin proposed as the new chairman [3] - Huatai Medical announced a board restructuring, nominating several candidates for its third board of directors, including current executives from Mindray Medical [4] - Hanyu Pharmaceutical reported the retirement of its executive director Pinxiang Yu and appointed two new executive directors, Shen Yaping and Tang Yangming [5] - GSK China appointed Sheng Feng as vice president, responsible for market access and commercial operations, effective December 1, 2025 [12] Executive Appointments - Medtronic appointed Larry Xu as vice president for orthopedic and neurosurgery business in China, effective November 10, 2025 [9] - Pfizer China announced the appointment of Su Tianyu as head of the broad market division, effective immediately [10][11] - Eli Lilly appointed Carole Ho as president of the neuroscience division, while Adrienne Brown was promoted to president of the immunology division [15] - Restore Medical appointed Chris Cleary, former senior vice president at Medtronic, as chairman of the board [18] Resignations - Johnson & Johnson announced the departure of Alex He, vice president and head of the PINS division, effective December 31, 2025 [8] - Several executives across various companies, including Chen Changbing from Sinopharm United and Wang Junbo from Guangyu Yuan, submitted their resignations due to work adjustments [3][5]

Investment Rating - The report does not explicitly provide an investment rating for the gynecological drug industry in China. Core Insights - The biopharmaceutical industry in China is experiencing structural optimization, valuation recovery, and confidence rebuilding, particularly in the Hong Kong market, where the 18A system supports enterprise value discovery [2][3]. - Gynecological drug companies are characterized by specialized positioning and differentiated competition, focusing on areas such as traditional Chinese medicine, innovative treatments for gynecological tumors, and hormone drugs, showcasing strong professional images and commercialization capabilities [2][3]. Summary by Sections Capital Market Performance of China's Biopharmaceutical Sector - The A-share market has shifted from a focus on scale to sustainable development, while the Hong Kong market has attracted international capital through the 18A system, leading to a gradual rebuilding of long-term confidence in the biopharmaceutical sector [3][25]. - The A-share biopharmaceutical sector has seen a total fundraising amount of 787 billion yuan from January to October 2025, with a peak of 2,451 billion yuan in 2021, indicating a transition from a capital overheating phase to a rational development phase [13][18]. - In the Hong Kong market, the total fundraising amount reached 789 billion HKD from January to October 2025, with a peak of 1,833 billion HKD in 2020, reflecting a significant improvement in the financing environment [27][28]. Market Position Assessment of Chinese Gynecological Drug Companies - The competitive landscape of gynecological drug companies is marked by a focus on specialized fields such as innovative gynecological tumor drugs and hormone treatments, with companies establishing differentiated competitive advantages [40]. - Qianjin Pharmaceutical is recognized as a leading player in the gynecological drug market, with a strong market presence in oral gynecological inflammation traditional Chinese medicine [40]. - Heng Rui Pharmaceutical is noted for its robust pipeline in gynecological tumor treatments, with eight drugs in development as of 2024 [40]. - Xianju Pharmaceutical specializes in hormone treatments, with a focus on steroid drugs, establishing a strong professional image in the gynecological field [40]. Introduction to Representative Listed Chinese Gynecological Drug Companies - Qianjin Pharmaceutical has a significant market share of 25.8% in oral gynecological inflammation traditional Chinese medicine, demonstrating strong sales performance even in challenging market conditions [45]. - Heng Rui Pharmaceutical's research and development pipeline includes multiple innovative treatments for gynecological tumors, indicating a solid commitment to this therapeutic area [52][53]. - Xianju Pharmaceutical leverages its expertise in steroid drugs to maintain a competitive edge in the gynecological drug market, with a focus on cost-effective production and high-quality formulations [58][61].

Core Viewpoint - The recent legal victory of Shanxi Guangyuyuan Traditional Chinese Medicine Co., Ltd. against a health company over trademark rights and unfair competition sets a new benchmark for intellectual property protection in the traditional Chinese medicine industry [1][3]. Group 1: Legal Case Summary - The case lasted for two years and resulted in a significant ruling that not only compensated Guangyuyuan for economic losses but also enhanced its brand reputation [1][2]. - The court recognized the "Guangyuyuan" trademark as a well-known trademark, confirming that the defendant's use of the name caused consumer confusion and constituted unfair competition [3]. - The compensation amount was doubled from 500,000 yuan to 1 million yuan, and the defendant was ordered to cease sales of infringing products in mainland China [3]. Group 2: Industry Context - The number of disputes involving time-honored brands has been increasing, with nearly 50% of such cases involving trademark imitation or malicious registration [1][4]. - The protection of traditional brands is supported by national policies, such as the "Intellectual Property Power Construction Outline (2021-2035)" which emphasizes the development and protection of traditional brands [2][4]. - The case highlights the challenges faced by traditional brands in protecting their intellectual property, including difficulties in evidence collection and high litigation costs [4]. Group 3: Company Performance - Guangyuyuan has seen a turnaround in its financial performance, with revenue exceeding 779 million yuan and net profit reaching approximately 76.86 million yuan in the first half of the year, marking a significant improvement [5]. - The company’s traditional production techniques have been recognized as national intangible cultural heritage, contributing to its brand value and market position [5]. - The company has initiated a "1541" development strategy to adapt to new industry dynamics and ensure sustainable growth [5].

Core Viewpoint - Shanxi Guangyuyuan Pharmaceutical Technology Co., Ltd. has been established with a registered capital of 50 million yuan, focusing on various pharmaceutical and healthcare services, fully owned by Guangyuyuan (600771) [1][2]. Company Information - The legal representative of the company is Chen Jianfeng [1][2]. - The registered capital is 50 million yuan [1][2]. - The company is located in Tai Gu District, Jinzhong City, Shanxi Province [2]. - The business scope includes drug wholesale, retail, sales of medicinal auxiliary materials, food sales, and internet information services related to pharmaceuticals [1][2]. Shareholder Information - The company is wholly owned by Guangyuyuan (600771) [1][2]. - The shareholder's contribution is 50 million yuan, with a holding percentage of 100% [2].